|
|
||||||||
RESEARCH |
Don C. Des Jarlais, Jessica Clark Newman, Molly Yancovitz, Denise Paone, and David Perlman are with the Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, NY. Don C. Des Jarlais is also with the National Development and Research Institutes, New York, NY. Dennis G. Fisher is with the Department of Psychology and Beth N. Trubatch is with the Intravenous Drug User (IVDU) Project, University of Alaska, Anchorage.
Correspondence: Requests for reprints should be sent to Don C. Des Jarlais, PhD, Beth Israel Medical Center/CDI, 1st Ave and 16th St, New York, NY 10003 (e-mail: dcdesjarla{at}aol.com).
| INTRODUCTION |
|---|
|
|
|---|
We compared 2 methods for delivering free hepatitis B vaccination to IDUs: (1) referral by research staff to local health care providers and (2) on-site vaccination at a syringe exchange program.
| METHODS |
|---|
|
|
|---|
The research study visits were scheduled for every 6 months and were conducted at a field site in the community. Participants were paid $25 for each interview session and $30 for each session in which testing results were provided. Initial referrals led to a very modest 7% of subjects receiving a first vaccination.1 Additional efforts were then made to increase vaccination. Free transportation was provided from the research site to the local clinics. After November 3, 1997, subjects were paid $10 when they provided proof of each individual vaccination. On March 18, 1999, the monetary incentive for the second and third vaccinations was increased to $20. On April 7, 2000, the incentive was increased to $50 for each vaccination.
Syringe Exchange On-Site Services
Pilot research funding was obtained to study the administration of hepatitis B vaccination at the Positive Health Project, a multiservice syringe exchange program in New York City.
From September 1998 through January 1999, 2 research associates were stationed at the syringe exchange program for 12 hours per week to recruit subjects for the hepatitis B vaccination study. Criteria for participation in the study were (a) having been a participant in the Positive Health Project for at least 1 month and (b) having injected drugs for no longer than 10 years. Informed consent was obtained, a short questionnaire was administered, and a blood sample for HBV testing was taken at the first visit. Subjects received $5 at the first study visit. They returned 1 week later to receive their HBV test results and, if they were eligible for hepatitis B vaccination, to receive their first vaccination; they received $5 at this second study visit. Subjects receiving the vaccine were asked to return 1 month later and 4 months later to receive the second and third injections and for the administration of short follow-up questionnaires. They received $10 at each of these follow-up visits.
Over a 6-month period from September 1998 to February 1999, a physician's assistant or a nurse was available to administer hepatitis B vaccine on 2 days per week for a total of 7 hours. From March 1999 to June 1999, vaccine administration was available for 5 hours on 1 day per week.
| RESULTS |
|---|
|
|
|---|
|
These 2 studies suggest that both modest financial incentives and convenient location greatly increase adherence to hepatitis B vaccination among IDUs.
We believe that researchers working with marginalized populations have an ethical obligation to identify better methods for providing health care to those populations, and research funding agencies have an ethical obligation to provide the extra resources required to ensure that research subjects receive the needed health care services.
| Footnotes |
|---|
Accepted for publication March 7, 2001.
| References |
|---|
|
|
|---|
2. Mezzelani P, Venturini L, Turrina G, Lugoboni F, Des Jarlais DC. High compliance with hepatitis B vaccination program among intravenous drug users. J Infect Dis.1991;163:923924.
3. Stancliff S, Perlman DC, Salomon N, Russell P. Provision of influenza and pneumococcal vaccines to injection drug users at a syringe exchange. J Subst Abuse Treat.2000;18:263265.[Medline]
4. Perlman DC, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange program. Am J Public Health.1997;87:862863.[Medline]
This article has been cited by other articles:
![]() |
G. L. Reynolds, D. G. Fisher, A. Jaffe, and J. Edwards Follow-up for medical care among drug users with hepatitis C. Eval Health Prof, December 1, 2006; 29(4): 355 - 366. [Abstract] [PDF] |
||||
![]() |
P. J. Lum, K. C. Ochoa, J. A. Hahn, K. Page Shafer, J. L. Evans, and A. R. Moss Hepatitis B Virus Immunization Among Young Injection Drug Users in San Francisco, Calif: The UFO Study Am J Public Health, June 1, 2003; 93(6): 919 - 923. [Full Text] [PDF] |
||||
![]() |
H. Hagan, H. Thiede, J. P. McGough, and E. R. Alexander Hepatitis B Vaccination Among Research Participants, Seattle, Washington Am J Public Health, November 1, 2002; 92(11): 1756 - 1756. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |